Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 888-364-4 | CAS number: 146569-48-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The test item was supposed to be tested with the OECD TG standardized in vitro skin sensitisation testing battery (OECD TG 442 C-E). However, OECD TG 442 C & D were not feasible with the test material due to its negligible solubility. A respective statement by the CRO testing the material was authored and attached to this dossier. Due to the fact that no decision can be made by OECD TG 442 E as stand alone assay, an in vivo skin sensitisation assay (OECD TG 406 - Buehler test) was performed.
The test item was evaluated in the “In Vitro Skin Sensitization by Human Cell Line Activation Test (h-CLAT) Method” as per the OECD guideline for testing of chemicals, No.: 442E. The measured expression levels of CD86 and CD54 cell surface markers are used for supporting the discrimination between skin sensitisers and non-sensitisers. Study was conducted to determine the cell viability (CV-75), expression level of CD86 and CD54 cell surface markers expression using human monocytic leukaemia cell line THP-1 in the h-CLAT method. Solubility test was conducted by RPMI 1640 media and dimethyl sulphoxide. Test item formed suspension in RPMI 1640 media at 500 mg/mL. On the day of testing, test item was prepared. Eleven concentrations were prepared for dose finding assay, RPMI media was used as solvent/vehicle, the final concentrations in plate was 4.883, 9.766, 19.531, 39.063, 78.125, 156.25, 312.5, 625, 1250, 2500 and 5000µg/mL. The CV75 value of the test item was determined at 3.3105 µg/mL. Based on the CV75 of dose finding assay, eight test concentrations of 1.109, 1.331, 1.597, 1.916, 2.299, 2.759, 3.311 and 3.973µg/mL were selected for CD86/CD54 expression measurement. Upregulation of the biomarkers CD86 and/or CD54 was observed in some of the tested concentration of the test item. EC150 value for CD86 was 1.13 and 1.4 µg/mL for run 1 and 2 respectively. EC200 for CD 54 was 1.51 and 2.07 µg/mL for run 1 and 2 respectively. Based on the expression levels of CD86 and CD54, the test item can be considered as "sensitiser" within the h-Clat assay. The data generated with this method is however not sufficient to conclude in isolation on the skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. Since further in vitro studies were not feasible, no conclusion on the sensitising properties via in vitro studies can be made. Hence, a subsequent in vivo study was performed.
The OECD TG 406 was performed as Buehler test method as it is regarded as the best option for this kind of test material. The study was conducted in two phases viz., pre study and the main study. For pre study, the dose of 25 mg and 50 mg of test item (moistened with 0.1 mL of 80% ethanol/water) were applied topically to the anterior left flank and posterior left flank respectively, whereas 75 mg and 100 mg of test item (moistened with 0.1 mL of 80% ethanol/water) were applied topically to the anterior right flank and posterior right flank respectively to each animal. No skin reactions were observed in any of the test dose approximately at 24 and 48 hours observation period after patch removal. In pre study (G1), no skin reactions were observed at the highest dose i.e. 100 mg of test item. Hence, 100 mg of test item was selected for induction and challenge phase of main study. The main study included three inductions on day 1, 8 and 15 and challenge on day 29. On induction day 1, 8 and 15, 0.1 mL of 80% ethanol/water and 100 mg of test item moistened with 0.1 mL of 80% ethanol/water were applied topically. On challenge day 29, 0.1 mL of acetone was topically applied to the anterior part of right flank, whereas 100 mg of test item moistened with 0.1 mL of acetone was topically applied to the posterior part of the right flank of all the animals. After 6 hours of contact period, the test patches were removed and the application sites were cleaned with normal saline swabs and dried. During induction phase, the test item application sites were observed for skin reactions approximately at 1 and 24 hours post removal of the test patches according to Draize method (1959) and during challenge phase the skin reactions were observed approximately at 24 and 48 hours post removal of the test patch according to Magnusson and Kligman grading scale. In induction phase, no skin reactions were observed in vehicle control and treatment group animals approximately at 1 and 24 hours of observation period of post patch removal. In challenge phase, theanimals did not reveal any skin reactions at anterior and posterior part of right flank of vehicle control and treatment group animals approximately at 24 and 48 hours of post patch removal. No clinical signs of toxicity and mortality were observed till termination. All the treated animals revealed physiologically normal increase in body weights during the observation period.
Under the experimental conditions employed and based on the results of the experiment, it is concluded that the test item did not show any skin sensitisation or allergic potential in Guinea pigs. Hence, the test item does not meet classification criteria according to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 February 2021 TO 24 June 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- As per OECD Guideline No. 442E
- Qualifier:
- according to guideline
- Guideline:
- other: As per OECD Guideline No. 442E
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- human Cell Line Activation Test (h-CLAT)
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch No.of test material: EX.14402.600
- Purity test date: 87.6%
- Solubility and stability of the test substance in the solvent/vehicle: RPMI 1640 media
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: RPMI 1640 media - Details of test system:
- THP-1 cell line [442E]
- Details on the study design:
- Skin sensitisation (In vitro test system) - Details on study design: Frozen stock of cryovial was thawed immediately at 37±1°C in the water bath.
cells were transferred into 15 mL falcon tube with 5 mL culture media, cells were centrifuged at 125g for 10 minutes. Cells pellet were transferred in to a sterile flask with RPMI-1640 supplemented with 10% Fetal Bovine Serum, antibiotics (1% Penicillin-Streptomycin) and 0.05 mM 2-Mercptoethanol
incubated at 37±1°C and 5±1% CO2 for 4 days.
On the day of testing, cells harvested from culture flask were resuspended with fresh culture medium at 2 × 106 cells/mL.
Then, cells are distributed into a 24 well flat-bottom plate with 500 µL (1 × 106 cells/well). The cells were qualified by conducting a reactivity test using the positive controls,
2,4-dinitrochlorobenzene (DNCB) and nickel sulfate (NiSO4) and the negative control, lactic acid (LA), two weeks after thawing. Both DNCB and NiSO4 produced a positive response and LA produced a negative response for both CD86 and CD54 cell surface markers.
A dose finding assay was performed to determine the CV75. The 75% cell viability (CV) of test chemical concentration are compared with RPMI media control.
The test item was prepared on the day of testing. Test item was dissolved or stably dispersed in medium as solvent/vehicle to final concentrations of 500 mg/mL (in medium) or 500 mg/mL (in DMSO).
Starting from the 500 mg/mL (in medium) stock solutions of the test chemicals, the following dilution steps was taken:
For medium as solvent/vehicle: Eleven stock solutions (eleven concentrations) were prepared, by two-fold serial dilutions using the corresponding solvent/vehicle. These stock solutions are then further diluted 50-fold into culture medium (working solutions). The top final concentration in the plate was 5000 µg/mL. - Vehicle / solvent control:
- cell culture medium
- Negative control:
- DL-Lactic acid
- Positive control:
- dinitrochlorobenzene (DNCB) [442E]
- Positive control results:
- DNCB was used as the positive control for CD86/CD54 expression measurement at a final single concentration in the plate was 4.0 μg/mL. To obtain a 4.0 μg/mL concentration of DNCB in the plate, a 2 mg/mL stock solution of DNCB in DMSO was prepared and further diluted 250-fold with culture medium to a 8 μg/mL working solution.
RFI values of CD86 for positive control is 412.55, 401.34 and of CD54 for positive control is 303.60, 364.43, for set 1 and set 2 respectively. - Group:
- test chemical
- Run / experiment:
- run/experiment 1
- Parameter:
- EC150, CD86 [442E]
- Value:
- 1.13 µg/mL
- Cell viability:
- 94.75 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Group:
- test chemical
- Run / experiment:
- run/experiment 2
- Parameter:
- EC150, CD86 [442E]
- Value:
- 1.4 µg/mL
- Cell viability:
- 94.18
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Group:
- test chemical
- Run / experiment:
- run/experiment 1
- Parameter:
- EC200, CD54 [442E]
- Value:
- 1.51 µg/mL
- Cell viability:
- 93.19 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Group:
- test chemical
- Run / experiment:
- run/experiment 2
- Parameter:
- EC200, CD54 [442E]
- Value:
- 2.07 µg/mL
- Cell viability:
- 89.96 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Other effects / acceptance of results:
- OTHER EFFECTS:
- Viability of 75 % was observed at 3.3105 µg/mL. All concentrations below showed respective higher viabilities.
DEMONSTRATION OF TECHNICAL PROFICIENCY:
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: YES
- Acceptance criteria met for positive control: YES
- Acceptance criteria met for variability between replicate measurements: YES
- Range of historical values if different from the ones specified in the test guideline: NO - Interpretation of results:
- study cannot be used for classification
- Remarks:
- The data generated with this method may not be sufficient to conclude in isolation on skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. Since further in vitro studies were not feasible, no conclusion on the sensitising properties via in vitro studies can be made. Hence, a subsequent in vivo study was performed (see Chapter 7.4.1).
- Conclusions:
- Based on the expression levels of CD86 and CD54, the test item in h-CLAT prediction is considered as “Sensitiser”.
The data generated with this method is however not sufficient to conclude in isolation on the skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. Since further in vitro studies were not feasible, no conclusion on the sensitising properties via in vitro studies can be made. Hence, a subsequent in vivo study was performed (see Chapter 7.4.1). - Executive summary:
The test item was evaluated in the “In Vitro Skin Sensitization by Human Cell Line Activation Test (h-CLAT) Method” as per the OECD guideline for testing of chemicals, No.: 442E. The measured expression levels of CD86 and CD54 cell surface markers are used for supporting the discrimination between skin sensitisers and non-sensitisers. Study was conducted to determine the cell viability (CV-75), expression level of CD86 and CD54 cell surface markers expression using human monocytic leukaemia cell line THP-1 in the h-CLAT method. Solubility test was conducted by RPMI 1640 media and dimethyl sulphoxide. Test item formed suspension in RPMI 1640 media at 500 mg/mL. On the day of testing, test item was prepared. Eleven concentrations were prepared for dose finding assay, RPMI media was used as solvent/vehicle, the final concentrations in plate was 4.883, 9.766, 19.531, 39.063, 78.125, 156.25, 312.5, 625, 1250, 2500 and 5000µg/mL. The CV75 value of the test item was determined at 3.3105 µg/mL. Based on the CV75 of dose finding assay, eight test concentrations of 1.109, 1.331, 1.597, 1.916, 2.299, 2.759, 3.311 and 3.973µg/mL were selected for CD86/CD54 expression measurement. Upregulation of the biomarkers CD86 and/or CD54 was observed in some of the tested concentration of the test item. EC150 value for CD86 was 1.13 and 1.4 µg/mL for run 1 and 2 respectively. EC200 for CD 54 was 1.51 and 2.07 µg/mL for run 1 and 2 respectively.
Hence, the test item can be consideres as "sensitiser" in the h-CLAT assay. However, the data generated with this method may not be sufficient to conclude in isolation on skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. Since further in vitro studies were not feasible, no conclusion on the sensitising properties via in vitro studies can be made. Hence, a subsequent in vivo study was performed (see Chapter 7.4.1).
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because the available in vitro test methods are not applicable for the substance and therefore an in vivo skin sensitisation study was conducted
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 November 2021 to 30 December 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- OECD Guideline for Testing of Chemicals, Section 4, Number 406, “Skin Sensitisation”, adopted on 17 July 1992 (Corrected on 14 June 2021)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- Buehler test
- Justification for non-LLNA method:
- Due to the negligible solubility and particulate constitution of the test item the test method according to Buehler was selected as the most appropriate test method for skin sensitisation for this test item.
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch No.: EX. 14402. 600
- Expiration date of the batch: Oct 2017
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient (21 to 29°C)
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: moistened with vehicle - Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Adita Biosys Private Limited
Plot No.: SPL-26, 2nd Phase,
KSSIDC Industrial Estate, Madhugiri Road,
Antharasanahalli, Tumakuru – 572 106,
Karnataka, INDIA
CPCSEA Registration No. 1868/PO/RcBt/S/16/CPCSEA
- Microbiological status of animals, when known: No abnormalities Detected
- Age at study initiation: 8 to 9 weeks
- Weight at study initiation: 340.74 g to 359.06 g
- Housing: polypropylene cage (size: L 430 x B 280 x H 190 mm)
- Diet (e.g. ad libitum): Altromin diet for guinea pigs (manufactured by Altromin Spezialfutter GmbH & Co. KG)
- Water (e.g. ad libitum): Deep bore-well water passed through Reverse osmosis unit
- Acclimation period: Pre-study: 18 November 2021 to 22 November 2021
Main-study: 18 November 2021 to 28 November 2021
- Indication of any skin lesions: No
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
- Humidity (%):
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light):
- IN-LIFE DATES: From: To: - Route:
- epicutaneous, occlusive
- Vehicle:
- other: 80% ethanol/water
- Concentration / amount:
- 100% w/v Test Item (100 mg of test item moistened with 0.1 mL of 80% ethanol/water for induction phase)
- Day(s)/duration:
- Day 1, Day 8 and Day 15
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- other: Acetone
- Concentration / amount:
- 100% w/v test item (100 mg of test item moistened with 0.1 mL of acetone for challenge phase)
- Day(s)/duration:
- Day 29
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- vehicle control - 10 animals
Test item - 20 animals - Details on study design:
- RANGE FINDING TESTS: The animals did not reveal any skin reactions after application of 100 mg of test item moistened with 0.1 mL of 80% ethanol/water at 24 hours and 48 hours after patch removal in the pre-study. Hence, 100 mg of test item moistened with 0.1 mL of 80% ethanol/water was selected for induction and 100 mg test item moistened with 0.1 mL of acetone for challenge phase of the main study
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 3
- Exposure period: Days 1, 8 and 15 (weekly once)
- Test groups: 1 (20 animals)
- Control group: 1 (10 animals)
- Site: left flank
- Frequency of applications: weekly once
- Duration: 3 weeks
- Concentrations: 100% w/v
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 1 day (6 hours)
- Exposure period: 6 hours
- Test groups: 1
- Control group: 1
- Site: right flank
- Concentrations: 100% w/v
- Evaluation (hr after challenge): 24 and 48
- Positive control substance(s):
- no
- Positive control results:
- The positive control was not included in this study as the reliability of the skin sensitisation was tested using 2-Mercaptobenzothiazole under study no.: BIO-ATX 3599. The positive control result is presented as Annexure 1 in study report.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100 mg
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100 mg
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Remarks on result:
- not measured/tested
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- positive control
- Remarks on result:
- not measured/tested
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the experimental conditions employed and based on the results of the experiment, it is concluded that the test item did not show any skin sensitisation or allergic potential in Guinea pigs. Hence, the test item does not meet classification criteria according to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals.
- Executive summary:
The study was conducted to evaluate the skin Sensitisation potential of the test item in Guinea Pigs by Buehler Test Method.
The study was conducted in two phases viz., pre study and the main study.For pre study, approximately 24 hours before treatment, fur from the right and left flank region was clipped closely using an electric hair clipper exposing an area of approximately 80 sq. cm.The dose of 25 mg and 50 mg of test item (moistened with 0.1 mL of 80% ethanol/water) were applied topically to the anterior left flank and posterior left flank respectively, whereas 75 mg and 100 mg of test item (moistened with 0.1 mL of 80% ethanol/water) were applied topically to the anterior right flank and posterior right flank respectively to each animal. No skin reactions were observed in any of the test dose approximately at 24 and 48 hours observation period after patch removal.
In pre study (G1), no skin reactions were observed at the highest dose i.e. 100 mg of test item. Hence, 100 mg of test item was selected for induction and challenge phase of main study.
The main study comprised of two groups, G2 (Vehicle control) and G3 (treatment). The main study included three inductions on day 1, 8 and 15 and challenge on day 29. Approximately 24 hours prior to initiation of the treatment, fur from the left and right flank was clipped closely using an electric hair clipper exposing an area of approximately 80 sq. cm. for induction and challenge phase of the experiment respectively.
On induction day 1, 8 and 15, 0.1 mL of 80% ethanol/water and 100 mg of test item moistened with 0.1 mL of 80% ethanol/water were applied topically on left flank region to G2 and G3 group animals respectively. On challenge day 29, 0.1 mL of acetone was topically applied to the anterior part of right flank, whereas 100 mg of test item moistened with 0.1 mL of acetone was topically applied to the posterior part of the right flank of all the animals. The test patches were covered by approximately 4×6 cm2cotton gauze and held in place with non-irritating adhesive tape and crepe bandage. After 6 hours of contact period, the test patches were removed and the application sites were cleaned with normal saline swabs and dried. During induction phase, the test item application sites were observed for skin reactions approximately at 1 and 24 hours post removal of the test patches according to Draize method (1959) and during challenge phase the skin reactions were observed approximately at 24 and 48 hours post removal of the test patch according to Magnusson and Kligman grading scale.
All the animals were observed once daily for clinical signs of toxicity and twice daily for mortality/morbidity during the experimental period. Individual animal body weight was recorded at receipt and on day 1 (before start of the treatment) and at termination for the pre study and main study animals.
In induction phase, no skin reactions were observed in vehicle control and treatment group animals approximately at 1 and 24 hours of observation period of post patch removal.
In challenge phase, theanimals did not reveal any skin reactions at anterior and posterior part of right flank of vehicle control and treatment group animals approximately at 24 and 48 hours of post patch removal.
No clinical signs of toxicity and mortality were observed till termination. All the treated animals revealed physiologically normal increase in body weights during the observation period.
Referenceopen allclose all
Test Item Concentrations (µg/mL) | RFI Values of test item: Set 1 | RFI Values of test item: Set 2 | ||
CD86 | CD54 | CD86 | CD54 | |
3.973 | 426.39 | 363.70 | 350.05 | 360.46 |
3.311 | 392.37 | 423.64 | 389.83 | 344.84 |
2.759 | 366.24 | 350.54 | 320.97 | 269.20 |
2.299 | 366.36 | 141.58 | 345.22 | 337.42 |
1.916 | 282.28 | 216.51 | 335.66 | 106.80 |
1.597 | 209.31 | 233.28 | 175.13 | 31.07 |
1.331 | 213.97 | 125.31 | 140.90 | 77.93 |
1.109 | 141.79 | 137.05 | 142.03 | 193.73 |
TABLE 1. EC150 (CD86), EC200 (CD54) AND PREDICTION OF THE TEST ITEM
Sl. No. | Details | CD86 | CD54 | EC150 (CD86) µg/mL | EC200 (CD54) µg/mL |
1 | Set-1 | RFI>150 | RFI>200 | 1.13 | 1.51 |
2 | Set-2 | RFI>150 | RFI>200 | 1.40 | 2.07 |
3 | Prediction | Positive | Positive | - | - |
Refer Appendix 2 and 3
ND: Not Determined, EC: Effective Concentration.
TABLE 2. CV-75 CONCENTRATION AND OVERALL PREDICTION OF THE TEST ITEM
CV-75 (µg/mL) | 3.3105 |
Prediction | Positive |
TABLE 3. SKIN REACTIONS SCORING RECORD DURING PRE STUDY
Group, Sex & Treatment | Animal No. | Site | Dose (mg) | 24hours* | 48hours* | ||
Ery | Ede | Ery | Ede | ||||
G1, Male & test item | Ge4859 | ALF | 25.0 | 0 | 0 | 0 | 0 |
PLF | 50.2 | 0 | 0 | 0 | 0 | ||
ARF | 75.1 | 0 | 0 | 0 | 0 | ||
PRF | 100.0 | 0 | 0 | 0 | 0 | ||
Ge4860 | ALF | 25.2 | 0 | 0 | 0 | 0 | |
PLF | 50.2 | 0 | 0 | 0 | 0 | ||
ARF | 75.2 | 0 | 0 | 0 | 0 | ||
PRF | 100.1 | 0 | 0 | 0 | 0 |
Ery: Erythema; Ede: Oedema; ALF: Anterior Left Flank; PLF: Posterior Left Flank; ARF: Anterior Right Flank;
PRF: Posterior Right Flank; 0: No erythema/No oedema
*: Observation time points after removal of the test patch
TABLE 4. SKIN REACTIONS SCORING RECORD DURING MAIN STUDY
Group, Sex & Treatment | Animal No. | Induction Phase | Challenge Phase Day 29 | |||||||||||||||
Induction I - Day 1 | Induction II - Day 8 | Induction III - Day 15 | Skin Reaction Score (Right Flank) | Sensitisation Rate (%) | ||||||||||||||
Skin Reaction Score (Left Flank) | Skin Reaction Score (Left Flank) | Skin Reaction Score (Left Flank) | ||||||||||||||||
1 hr* | 24 hrs* | 1 hr* | 24 hrs* | 1 hr* | 24 hrs* | 24 hrs* | 48 hrs* | |||||||||||
Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Post | Ant | Post | Ant | |||
G2, Male & Vehicle Control | Ge4861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ge4862 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4863 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4864 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4865 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4866 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4867 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4868 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4869 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Ge4870 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ery: Erythema; Ede: Oedema; hr(s): Hour(s); 0: No Erythema/Oedema; Post: Posterior part (test item); Ant: Anterior part (vehicle control); 0: No visible change for challenge scoring
*: Observation time points after removal of the test patch.
TABLE 4 (Contd…). SKIN REACTIONS SCORING RECORD DURING MAIN STUDY
Group, Sex & Treatment | Animal No. | Induction Phase | Challenge Phase Day 29 | ||||||||||||||||
Induction I - Day 1 | Induction II - Day 8 | Induction III - Day 15 | Skin Reaction Score (Right Flank) | Sensitisation Rate (%) | |||||||||||||||
Skin Reaction Score (Left Flank) | Skin Reaction Score (Left Flank) | Skin Reaction Score (Left Flank) | |||||||||||||||||
1 hr* | 24 hrs* | 1 hr* | 24 hrs* | 1 hr* | 24 hrs* | 24 hrs* | 48 hrs* | ||||||||||||
Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Ery | Ede | Post | Ant | Post | Ant | ||||
G3, Male & test item | Ge4871 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Ge4872 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4873 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4874 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4875 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4876 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4877 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4878 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4879 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4880 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4881 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4882 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4883 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4884 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4885 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4886 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4887 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4888 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4889 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ge4890 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Ery: Erythema; Ede: Oedema; hr(s): Hour(s); 0: No Erythema/Edema; Post: Posterior part (test item); Ant: Anterior part (vehicle control); 0: No visible change for challenge scoring
*: Observation time points after removal of the test patch.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the expression levels of CD86 and CD54, the test item in h-CLAT prediction is considered as “Sensitiser”. The data generated with this method is however not sufficient to conclude in isolation on the skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. Since further in vitro studies were not feasible, no conclusion on the sensitising properties via in vitro studies can be made. Hence, a subsequent in vivo study was performed.
The subsequent in vivo skin sensitising study did not show any skin sensitisation or allergic potential in Guinea pigs. Hence, the test item does not meet classification criteria according to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.